German family-owned pain focused drugmaker Grünenthal has announced the acquisition of USA-based Valinor Pharma.
The deal has a total value of around $250 million inclusive of all royalty obligations and brings in rights to its product Movantik (naloxegol). Grünenthal will finance the transaction using available liquidity.
Movantik is indicated for the oral treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. The transaction further expands Grünenthal’s portfolio of established medicines and adds to the company’s growing US business. Gross sales from Movantik in the USA reached over $200 million in 2023.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze